SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: tom jones who wrote (2073)7/7/1998 11:11:00 PM
From: John Metcalf  Respond to of 4676
 
Tom, FDA committee meetings are open to the public, and are often reported in the press, when there is sufficient interest. Trading in a stock is usually halted during the Cmte meeting.

A vote or votes are taken at the meeting and reported, so you will know whether the committee finds Fomivirsen effective and safe. The FDA usually agrees with committee recommendations, but can take some time (measured in months) to resolve labeling issues and production issues.



To: tom jones who wrote (2073)7/16/1998 9:52:00 PM
From: DTselentis  Read Replies (1) | Respond to of 4676
 
Wasn't Isis's drug granted Priority Review by the FDA because it could be a great improvement over existing therapies ? Why would the FDA not want to approve a drug if no effective therapy exists. Its seems to me that if the drug can improve on existing therapies----even in a relatively small amount of patients the FDA would look toward approval.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News